Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 4, 2019 19:13 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 58,717 | $128.97 | $7,572,790.21 |
DisclosureSEC source: 0001209191-19-015363 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,015,304 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.85 to $129.345, inclusive. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 19:13 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 106,854 | $128.55 | $13,736,081.70 |
DisclosureSEC source: 0001209191-19-015363 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,074,021 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.85 to $128.84, inclusive. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 19:13 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 44,429 | $127.45 | $5,662,342.76 |
DisclosureSEC source: 0001209191-19-015363 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,180,875 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.845 to $127.84, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:51 UTC |
Zakrowski Donald AChief Accounting Officer
|
SaleCommon Stock | 1,000 | $127.01 | $127,010.00 |
DisclosureSEC source: 0000059478-19-000127 · wf-form4_155181906182227.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,595 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2018. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 18:25 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 33,200 | $127.45 | $4,231,472.80 |
DisclosureSEC source: 0001209191-19-014881 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,225,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.2472 to $127.6522, inclusive. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 18:25 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 166,800 | $126.58 | $21,113,544.00 |
DisclosureSEC source: 0001209191-19-014881 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,258,504 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.1837 to $127.1198, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 21:06 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 195,000 | $124.19 | $24,217,635.00 |
DisclosureSEC source: 0001209191-19-012949 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,425,304 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.90 to $124.74, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:53 UTC |
Walker KarenDirector
|
GrantCommon Stock | 81 | $122.13 | $9,892.53 |
DisclosureSEC source: 0000059478-19-000113 · wf-form4_155069597015640.xml · nonDerivative · entry 1 Walker Karen · CIK 0001642519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292 Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:53 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 16 | $122.13 | $1,954.08 |
DisclosureSEC source: 0000059478-19-000114 · wf-form4_155069602441995.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,263 Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:55 UTC |
MARRAM ELLEN RDirector
|
GrantCommon Stock | 55 | $122.13 | $6,717.15 |
DisclosureSEC source: 0000059478-19-000115 · wf-form4_155069608721083.xml · nonDerivative · entry 1 MARRAM ELLEN R · CIK 0001234124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,255 Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:56 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 87 | $122.13 | $10,625.31 |
DisclosureSEC source: 0000059478-19-000116 · wf-form4_155069614700112.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,294 Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:56 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 89 | $122.13 | $10,869.57 |
DisclosureSEC source: 0000059478-19-000117 · wf-form4_155069620500460.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,462 Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 18:35 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 21,380 | $123.14 | $2,632,690.44 |
DisclosureSEC source: 0001209191-19-011431 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,620,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.00 to $123.32, inclusive. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 18:35 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 183,620 | $122.40 | $22,475,822.48 |
DisclosureSEC source: 0001209191-19-011431 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,641,684 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.00 to $122.995, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 20:52 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000112 · wf-form4_155069590817698.xml · derivative · entry 6 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by partner Disclosed balance after: 97 Underlying: Common Stock · 48 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three installments, 48 on February 16, 2018; 48 on February 16, 2019; and 97 on February 16, 2020. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 20:52 UTC |
Norton JohnaSenior VP, Global Quality
|
Tax withholdingCommon Stock | 17 | $122.48 | $2,082.16 |
DisclosureSEC source: 0000059478-19-000112 · wf-form4_155069590817698.xml · nonDerivative · entry 2 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by partner Disclosed balance after: 65 Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 20:52 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionCommon Stock | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000112 · wf-form4_155069590817698.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Indirect · by partner Disclosed balance after: 82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 20:37 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
SaleCommon Stock | 25,000 | $121.00 | $3,025,000.00 |
DisclosureSEC source: 0000059478-19-000103 · wf-form4_155069505836534.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,962 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018. Read SEC document |
| February 11, 2019 Filed Jun 4, 2019 17:57 UTC |
Harrington Michael JSenior VP and General Counsel
|
GiftCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000199 · wf-form4_155967100770907.xml · nonDerivative · entry 3 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 62,500 F3 · kind: Bonafide gift of securities for the benefit of reporting persons spouse. Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 11, 2019 Filed Jun 4, 2019 17:57 UTC |
Harrington Michael JSenior VP and General Counsel
|
GiftCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000199 · wf-form4_155967100770907.xml · nonDerivative · entry 2 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,800 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:00 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantRestricted Stock Unit · Derivative | 4,896 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000049 · wf-form4_154949760502486.xml · derivative · entry 3 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,896 Underlying: Common Stock · 4,896 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:00 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 7,411 | $120.17 | $890,579.87 |
DisclosureSEC source: 0000059478-19-000049 · wf-form4_154949760502486.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,820 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:02 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
GrantRestricted Stock Unit · Derivative | 20,397 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000051 · wf-form4_154949776150306.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,397 Underlying: Common Stock · 20,397 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:02 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
GrantCommon Stock | 26,681 | $120.17 | $3,206,255.77 |
DisclosureSEC source: 0000059478-19-000051 · wf-form4_154949776150306.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,961 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:10 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 13,055 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000053 · wf-form4_154949824035558.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,055 Underlying: Common Stock · 13,055 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:10 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 19,404 | $120.17 | $2,331,778.68 |
DisclosureSEC source: 0000059478-19-000053 · wf-form4_154949824035558.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,509 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:16 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantRestricted Stock Unit · Derivative | 18,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000055 · wf-form4_154949856017746.xml · derivative · entry 3 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,765 Underlying: Common Stock · 18,765 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:16 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 28,155 | $120.17 | $3,383,386.35 |
DisclosureSEC source: 0000059478-19-000055 · wf-form4_154949856017746.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,299 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:22 UTC |
Norton JohnaSenior VP, Global Quality
|
GrantCommon Stock | 2,958 | $120.17 | $355,462.86 |
DisclosureSEC source: 0000059478-19-000057 · wf-form4_154949893755930.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,817 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:29 UTC |
Ricks David ADirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 69,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000059 · wf-form4_154949934152598.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,350 Underlying: Common Stock · 69,350 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:29 UTC |
Ricks David ADirector · President & CEO
|
GrantCommon Stock | 26,567 | $120.17 | $3,192,556.39 |
DisclosureSEC source: 0000059478-19-000059 · wf-form4_154949934152598.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,790 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:36 UTC |
Shah Aarti S.SVP & CIO
|
GrantCommon Stock | 5,939 | $120.17 | $713,689.63 |
DisclosureSEC source: 0000059478-19-000061 · wf-form4_154949977670609.xml · nonDerivative · entry 1 Shah Aarti S. · CIK 0001725292 · SVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,224 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:39 UTC |
Skovronsky DanielSVP, CSO, and Pres. LRL
|
GrantCommon Stock | 15,619 | $120.17 | $1,876,935.23 |
DisclosureSEC source: 0000059478-19-000063 · wf-form4_154949997417000.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,818 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:53 UTC |
White Anne E.SVP & Pres-Lilly Oncology
|
GrantCommon Stock | 7,246 | $120.17 | $870,751.82 |
DisclosureSEC source: 0000059478-19-000065 · wf-form4_154950080990103.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,043 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:58 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantRestricted Stock Unit · Derivative | 16,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000067 · wf-form4_154950111330041.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,317 Underlying: Common Stock · 16,317 shares Expires 2020-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:58 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantCommon Stock | 21,224 | $120.17 | $2,550,488.08 |
DisclosureSEC source: 0000059478-19-000067 · wf-form4_154950111330041.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,806 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 01:02 UTC |
Smiley Joshua LSVP and CFO
|
GrantCommon Stock | 9,954 | $120.17 | $1,196,172.18 |
DisclosureSEC source: 0000059478-19-000069 · wf-form4_154950131872045.xml · nonDerivative · entry 1 Smiley Joshua L · CIK 0001725189 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 01:10 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 8,592 | $120.17 | $1,032,500.64 |
DisclosureSEC source: 0000059478-19-000073 · wf-form4_154950181957323.xml · nonDerivative · entry 4 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,645 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 01:10 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 4,635 | $120.17 | $556,987.95 |
DisclosureSEC source: 0000059478-19-000073 · wf-form4_154950181957323.xml · nonDerivative · entry 3 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 57,319 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 01:29 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 3,243 | $120.17 | $389,711.31 |
DisclosureSEC source: 0000059478-19-000075 · wf-form4_154950296898330.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,593 Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:39 UTC Amendment |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 8,593 | $120.17 | $1,032,620.81 |
DisclosureSEC source: 0000059478-19-000104 · wf-form4a_155069516133288.xml · nonDerivative · entry 2 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,646 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:39 UTC Amendment |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 4,690 | $120.17 | $563,597.30 |
DisclosureSEC source: 0000059478-19-000104 · wf-form4a_155069516133288.xml · nonDerivative · entry 1 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 57,374 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:40 UTC Amendment |
Smiley Joshua LSVP and CFO
|
GrantCommon Stock | 9,955 | $120.17 | $1,196,292.35 |
DisclosureSEC source: 0000059478-19-000105 · wf-form4a_155069523325169.xml · nonDerivative · entry 1 Smiley Joshua L · CIK 0001725189 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,984 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:42 UTC Amendment |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 28,156 | $120.17 | $3,383,506.52 |
DisclosureSEC source: 0000059478-19-000106 · wf-form4a_155069532226405.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,300 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:43 UTC Amendment |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
GrantCommon Stock | 26,682 | $120.17 | $3,206,375.94 |
DisclosureSEC source: 0000059478-19-000107 · wf-form4a_155069540134470.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,962 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:45 UTC Amendment |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 19,405 | $120.17 | $2,331,898.85 |
DisclosureSEC source: 0000059478-19-000108 · wf-form4a_155069548851317.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,510 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:46 UTC Amendment |
Norton JohnaSenior VP, Global Quality
|
GrantCommon Stock | 2,960 | $120.17 | $355,703.20 |
DisclosureSEC source: 0000059478-19-000109 · wf-form4a_155069557190530.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,819 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:47 UTC Amendment |
Shah Aarti S.SVP & CIO
|
GrantCommon Stock | 5,940 | $120.17 | $713,809.80 |
DisclosureSEC source: 0000059478-19-000110 · wf-form4a_155069565002259.xml · nonDerivative · entry 1 Shah Aarti S. · CIK 0001725292 · SVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,225 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 04, 2019 Filed Feb 20, 2019 20:50 UTC Amendment |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 3,245 | $120.17 | $389,951.65 |
DisclosureSEC source: 0000059478-19-000111 · wf-form4a_155069579900786.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,595 F1 · shares: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount acquired in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:43 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000032 · wf-form4_154941021277393.xml · derivative · entry 4 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2019-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.